Muaiad Kittaneh, Global Head of RandD and Scintific Strategy at Syneos Health, shared a post on LinkedIn by Xtalks, adding:
“Minimal Residual Disease (MRD) is transitioning from a translational endpoint to a strategic decision tool in oncology drug development.
The critical question is no longer its validity, but its optimal deployment across:
- dose optimization
- cohort expansion
- registrational strategy.
At the same time, advancing MRD as a biomarker and intermediate endpoint requires careful alignment across clinical pharmacology, assay validation, and regulatory expectations.
Programs that integrate MRD with intent, rather than retrospectively, will likely define the next wave of efficient development in oncology.
Looking forward to discussing how we operationalize MRD within modern development strategy.”
Quoting Xtalks’s post:
“Join us to move beyond the conceptual promise of Minimal Residual Disease (MRD) and operationalize it as a central pillar of your oncology strategy with Wael Harb, Zohra Lomri, Pierre-Olivier T., Muaiad Kittaneh, MD, MBA, FACP, and Rafat Abonour in this webinar hosted by Syneos Health.
In 2026, the pressure to generate decision-ready data faster than ever means MRD is no longer just a translational interest; it is a vital tool for dose selection, cohort expansion, and registration-enabling pathways.
Register now to learn how to bridge the gap between scientific rigor and operational feasibility.”
Other Articles Featuring Muaiad Kittaneh on OncoDaily.